Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 07, 2022 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Sep. 30, 2022 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Entity Registrant Name | AURA BIOSCIENCES, INC. | |
Entity Central Index Key | 0001501796 | |
Entity File Number | 001-40971 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 32-0271970 | |
Entity Address, Address Line One | 80 Guest Street | |
Entity Address, City or Town | Boston | |
Entity Address, State or Province | MA | |
Entity Address, Postal Zip Code | 02135 | |
City Area Code | 617 | |
Local Phone Number | 500-8864 | |
Entity Interactive Data Current | Yes | |
Entity Current Reporting Status | No | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Shell Company | false | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Title of 12(b) Security | Common Stock, par value $0.00001 per share | |
Trading Symbol | AURA | |
Security Exchange Name | NASDAQ | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity Bankruptcy Proceedings, Reporting Current | true | |
Entity Common Stock, Shares Outstanding | 29,334,729 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 61,110 | $ 149,063 |
Marketable securities | 50,409 | |
Restricted cash and deposits | 182 | 23 |
Prepaid expenses and other current assets | 4,207 | 4,618 |
Total current assets | 115,908 | 153,704 |
Restricted cash and deposits, net of current portion | 768 | 125 |
Right of use assets - operating lease | 20,996 | 950 |
Property and equipment, net | 5,475 | 5,251 |
Total Assets | 143,147 | 160,030 |
Current liabilities: | ||
Accounts payable | 1,724 | 2,401 |
Short-term operating lease liability | 2,942 | 615 |
Accrued expenses and other current liabilities | 5,298 | 4,339 |
Total current liabilities | 9,964 | 7,355 |
Long-term operating lease liability | 18,129 | 360 |
Total Liabilities | 28,093 | 7,715 |
Commitments and Contingencies (Note 12) | ||
Stockholders Equity: | ||
Common stock, $0.00001 par value, 150,000,000 authorized at September 30, 2022 and December 31, 2021, and 29,283,285 and 29,211,643 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively | ||
Additional paid-in capital | 309,542 | 304,452 |
Accumulated deficit | (194,341) | (152,137) |
Accumulated other comprehensive loss | (147) | |
Total Stockholders' Equity | 115,054 | 152,315 |
Total Liabilities and Stockholders Equity | $ 143,147 | $ 160,030 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Sep. 30, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Common stock, par value | $ 0.00001 | $ 0.00001 |
Common stock, shares authorized | 150,000,000 | 150,000,000 |
Common stock, shares issued | 29,283,285 | 29,211,643 |
Common stock, shares outstanding | 29,283,285 | 29,211,643 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Operating Expenses: | ||||
Research and development | $ 11,293 | $ 6,365 | $ 29,079 | $ 17,182 |
General and administrative | 4,762 | 2,530 | 13,603 | 6,441 |
Total operating expenses | 16,055 | 8,895 | 42,682 | 23,623 |
Total operating loss | (16,055) | (8,895) | (42,682) | (23,623) |
Other income (expense): | ||||
Interest income, including amortization and accretion income | 483 | 5 | 802 | 8 |
Realized loss on marketable securities | (9) | (9) | ||
Loss on disposal of assets | (313) | (318) | (3) | |
Other income (expense) | (7) | 52 | 3 | 1 |
Total other income (expense) | 154 | 57 | 478 | 6 |
Net loss | (15,901) | (8,838) | (42,204) | (23,617) |
Net loss attributable to common stockholders - basic and diluted (Note 13) | $ (15,901) | $ (12,506) | $ (42,204) | $ (33,244) |
Net loss per share attributable to common stockholders - basic | $ (0.54) | $ (28.33) | $ (1.44) | $ (77.93) |
Net loss per share attributable to common stockholders - diluted | $ (0.54) | $ (28.33) | $ (1.44) | $ (77.93) |
Weighted average common stock outstanding - basic | 29,273,577 | 441,448 | 29,246,449 | 426,604 |
Weighted average common stock outstanding - diluted | 29,273,577 | 441,448 | 29,246,449 | 426,604 |
Comprehensive loss: | ||||
Net loss | $ (15,901) | $ (8,838) | $ (42,204) | $ (23,617) |
Other comprehensive items: | ||||
Unrealized loss on marketable securities | (19) | (147) | ||
Total other comprehensive loss | (19) | (147) | ||
Total comprehensive loss | $ (15,920) | $ (8,838) | $ (42,351) | $ (23,617) |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss Amount | Series A Convertible Preferred Stock | Series A-1 Convertible Preferred Stock | Series A-2 Convertible Preferred Stock | Series B Convertible Preferred Stock | Series C-1 and C-2 Convertible Preferred Stock | Series D-1 and D-2 Convertible Preferred Stock | Series E Convertible Preferred Stock |
Beginning Balance at Dec. 31, 2020 | $ (108,713) | $ 8,173 | $ (116,886) | |||||||||
Convertible preferred stock, Beginning Balance at Dec. 31, 2020 | $ 3,368 | $ 7,837 | $ 5,373 | $ 20,806 | $ 41,099 | $ 49,593 | ||||||
Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2020 | 1,701,141 | 3,298,732 | 4,324,998 | 22,531,819 | 91,327,903 | 72,348,452 | ||||||
Beginning Balance, Shares at Dec. 31, 2020 | 381,123 | |||||||||||
Issuance of convertible preferred stock | $ 6,982 | $ 80,251 | ||||||||||
Issuance of convertible preferred stock, Shares | 10,128,771 | 102,671,041 | ||||||||||
Stock-based compensation expense | 185 | 185 | ||||||||||
Stock option exercises | 265 | 265 | ||||||||||
Stock option exercises, Shares | 54,296 | |||||||||||
Net loss | (5,927) | (5,927) | ||||||||||
Ending Balance at Mar. 31, 2021 | (114,190) | 8,623 | (122,813) | |||||||||
Convertible preferred stock, Ending Balance at Mar. 31, 2021 | $ 3,368 | $ 7,837 | $ 5,373 | $ 20,806 | $ 41,099 | $ 56,575 | $ 80,251 | |||||
Convertible preferred stock, Ending Balance, Shares at Mar. 31, 2021 | 1,701,141 | 3,298,732 | 4,324,998 | 22,531,819 | 91,327,903 | 82,477,223 | 102,671,041 | |||||
Ending Balance, Shares at Mar. 31, 2021 | 435,419 | |||||||||||
Beginning Balance at Dec. 31, 2020 | (108,713) | 8,173 | (116,886) | |||||||||
Convertible preferred stock, Beginning Balance at Dec. 31, 2020 | $ 3,368 | $ 7,837 | $ 5,373 | $ 20,806 | $ 41,099 | $ 49,593 | ||||||
Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2020 | 1,701,141 | 3,298,732 | 4,324,998 | 22,531,819 | 91,327,903 | 72,348,452 | ||||||
Beginning Balance, Shares at Dec. 31, 2020 | 381,123 | |||||||||||
Net loss | (23,617) | |||||||||||
Ending Balance at Sep. 30, 2021 | (131,015) | 9,488 | (140,503) | |||||||||
Convertible preferred stock, Ending Balance at Sep. 30, 2021 | $ 3,368 | $ 7,837 | $ 5,373 | $ 20,806 | $ 41,099 | $ 56,575 | $ 80,246 | |||||
Convertible preferred stock, Ending Balance, Shares at Sep. 30, 2021 | 1,701,141 | 3,298,732 | 4,324,998 | 22,531,819 | 91,327,903 | 82,477,223 | 102,671,041 | |||||
Ending Balance, Shares at Sep. 30, 2021 | 442,717 | |||||||||||
Beginning Balance at Mar. 31, 2021 | (114,190) | 8,623 | (122,813) | |||||||||
Convertible preferred stock, Beginning Balance at Mar. 31, 2021 | $ 3,368 | $ 7,837 | $ 5,373 | $ 20,806 | $ 41,099 | $ 56,575 | $ 80,251 | |||||
Convertible preferred stock, Beginning Balance, Shares at Mar. 31, 2021 | 1,701,141 | 3,298,732 | 4,324,998 | 22,531,819 | 91,327,903 | 82,477,223 | 102,671,041 | |||||
Beginning Balance, Shares at Mar. 31, 2021 | 435,419 | |||||||||||
Stock-based compensation expense | 271 | 271 | ||||||||||
Stock option exercises | 20 | 20 | ||||||||||
Stock option exercises, Shares | 3,649 | |||||||||||
Net loss | (8,852) | (8,852) | ||||||||||
Ending Balance at Jun. 30, 2021 | (122,751) | 8,914 | (131,665) | |||||||||
Convertible preferred stock, Ending Balance at Jun. 30, 2021 | $ 3,368 | $ 7,837 | $ 5,373 | $ 20,806 | $ 41,099 | $ 56,575 | ||||||
Convertible preferred stock, Ending Balance, Shares at Jun. 30, 2021 | 1,701,141 | 3,298,732 | 4,324,998 | 22,531,819 | 91,327,903 | 82,477,223 | 102,671,041 | |||||
Ending Balance, Shares at Jun. 30, 2021 | 439,068 | 80,251 | ||||||||||
Stock-based compensation expense | 554 | 554 | ||||||||||
Stock option exercises | 20 | 20 | ||||||||||
Stock option exercises, Shares | 3,649 | |||||||||||
Other | $ (5) | |||||||||||
Net loss | (8,838) | (8,838) | ||||||||||
Ending Balance at Sep. 30, 2021 | (131,015) | 9,488 | (140,503) | |||||||||
Convertible preferred stock, Ending Balance at Sep. 30, 2021 | $ 3,368 | $ 7,837 | $ 5,373 | $ 20,806 | $ 41,099 | $ 56,575 | $ 80,246 | |||||
Convertible preferred stock, Ending Balance, Shares at Sep. 30, 2021 | 1,701,141 | 3,298,732 | 4,324,998 | 22,531,819 | 91,327,903 | 82,477,223 | 102,671,041 | |||||
Ending Balance, Shares at Sep. 30, 2021 | 442,717 | |||||||||||
Beginning Balance at Dec. 31, 2021 | 152,315 | 304,452 | (152,137) | |||||||||
Beginning Balance, Shares at Dec. 31, 2021 | 29,211,643 | |||||||||||
Stock-based compensation expense | 1,594 | 1,594 | ||||||||||
Stock option exercises | 17 | 17 | ||||||||||
Stock option exercises, Shares | 5,593 | |||||||||||
Unrealized loss on marketable securities | (5) | $ (5) | ||||||||||
Net loss | (12,835) | (12,835) | ||||||||||
Ending Balance at Mar. 31, 2022 | 141,086 | 306,063 | (164,972) | $ (5) | ||||||||
Ending Balance, Shares at Mar. 31, 2022 | 29,217,236 | |||||||||||
Beginning Balance at Dec. 31, 2021 | 152,315 | $ 304,452 | $ (152,137) | |||||||||
Beginning Balance, Shares at Dec. 31, 2021 | 29,211,643 | |||||||||||
Unrealized loss on marketable securities | (147) | |||||||||||
Net loss | (42,204) | |||||||||||
Ending Balance at Sep. 30, 2022 | $ 115,054 | |||||||||||
Ending Balance, Shares at Sep. 30, 2022 | 115,054 | 29,283,285 | 309,542 | (194,341) | (147) | |||||||
Beginning Balance at Mar. 31, 2022 | $ 141,086 | $ 306,063 | $ (164,972) | $ (5) | ||||||||
Beginning Balance, Shares at Mar. 31, 2022 | 29,217,236 | |||||||||||
Stock-based compensation expense | 1,287 | 1,287 | ||||||||||
Stock option exercises | 309 | 309 | ||||||||||
Stock option exercises, Shares | 49,612 | |||||||||||
Unrealized loss on marketable securities | (123) | (123) | ||||||||||
Net loss | (13,468) | (13,468) | ||||||||||
Ending Balance at Jun. 30, 2022 | 129,091 | 307,659 | (178,440) | (128) | ||||||||
Ending Balance, Shares at Jun. 30, 2022 | 29,266,848 | |||||||||||
Stock-based compensation expense | 1,717 | 1,717 | ||||||||||
Stock option exercises | 104 | 104 | ||||||||||
Stock option exercises, Shares | 16,437 | |||||||||||
Other | 62 | $ 62 | ||||||||||
Unrealized loss on marketable securities | (19) | $ (19) | ||||||||||
Net loss | (15,901) | $ (15,901) | ||||||||||
Ending Balance at Sep. 30, 2022 | $ 115,054 | |||||||||||
Ending Balance, Shares at Sep. 30, 2022 | 115,054 | 29,283,285 | 309,542 | (194,341) | (147) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity Deficit (Unaudited) (Parenthetical) $ in Thousands | 3 Months Ended |
Mar. 31, 2021 USD ($) | |
Series D Tranche 2 Convertible Preferred Stock | |
Stock issuance cost, net | $ 18 |
Series E Convertible Preferred Stock | |
Stock issuance cost, net | $ 232 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash flows from operating activities: | ||
Net loss | $ (42,204) | $ (23,617) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation expense | 854 | 601 |
Stock-based compensation expense | 4,598 | 1,010 |
Accretion on marketable securities | (299) | |
Loss on disposal of property and equipment | (318) | (3) |
Other | 113 | 3 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other assets | 411 | (566) |
Accounts payable | (678) | 891 |
Accrued expenses and other liabilities | 935 | 1,357 |
Net cash used in operating activities | (36,588) | (20,324) |
Cash flows from investing activities: | ||
Purchases of property and equipment | (736) | (1,306) |
Purchase of marketable securities | (71,266) | |
Proceeds from sale of marketable securities | 9 | |
Maturities of marketable securities | 21,000 | |
Net cash used in investing activities | (50,993) | (1,306) |
Cash flows from financing activities: | ||
Proceeds from exercise of stock options | 430 | 305 |
Payment made for deferred offering costs | (1,416) | |
Net cash provided by financing activities | 430 | 86,117 |
Net (decrease) increase in cash, cash equivalents and restricted cash | (87,151) | 64,487 |
Cash, cash equivalents and restricted cash at beginning of period | 149,211 | 17,487 |
Cash, cash equivalents and restricted cash at end of period | 62,060 | 81,974 |
Supplemental disclosure of cash flow information: | ||
Purchases of property and equipment in accounts payable and accrued expenses and other liabilities | 24 | 159 |
Initial measurement of right-of-use assets and lease liabilities for operating lease | $ 21,210 | 536 |
Remeasurement of right-of-use assets and lease liabilities for lease modification | 390 | |
Right-of-use assets obtained in exchange for operating lease liabilities | 516 | |
Series D Convertible Preferred Stock | ||
Cash flows from financing activities: | ||
Proceeds from issuance of convertible preferred stock, net of issuance costs | 6,982 | |
Series E Convertible Preferred Stock | ||
Cash flows from financing activities: | ||
Proceeds from issuance of convertible preferred stock, net of issuance costs | $ 80,246 |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows (Unaudited) - Reconciliation of Cash, Cash Equivalents, and Restricted Cash - USD ($) $ in Thousands | Sep. 30, 2022 | Sep. 30, 2021 |
Statement of Cash Flows [Abstract] | ||
Cash and cash equivalents, end of period | $ 61,110 | $ 81,829 |
Short-term restricted cash, end of period | 182 | 20 |
Long-term restricted cash, end of period | 768 | 125 |
Cash, cash equivalents and restricted cash at end of period | $ 62,060 | $ 81,974 |
Description of Business
Description of Business | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Description of Business | 1. Description of Business Aura Biosciences, Inc. (the “Company” or “Aura”) is a clinical-stage biotechnology company envisioning a new way to treat cancer. Leveraging a novel targeted oncology platform, the Company has the goal to develop a new standard of care across multiple cancer indications. Within these unaudited condensed consolidated financial statements, unless the context otherwise requires, references to the Company or Aura refer to Aura Biosciences, Inc and its subsidiary on a consolidated basis. The Company's initial focus is on ocular and urologic oncology where the disease is diagnosed early and there is a high unmet medical need. The Company's proprietary platform enables the targeting of a broad range of solid tumors using Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. The Company's VDCs are largely agnostic to tumor type and can recognize tumor associated glycosaminoglycans with unique heparan sulphate epitopes that are expressed on the cell surface of many tumor cells and in the tumor microenvironment. Belzupacap sarotalocan, the Company's first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved where the standard of care leaves many patients with blindness. The Company is also developing belzupacap sarotalocan for additional ocular oncology indications, including choroidal metastases, and in non-muscle invasive bladder cancer, or NMIBC. Aura’s headquarters are located in Boston, Massachusetts. The Company’s operations to date have consisted primarily of conducting research and development and raising capital. The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, the successful development and commercialization of products, fluctuations in operating results and financial risks, need for additional financing or alternative means of financial support or both to fund its current operating plan, protection of proprietary technology and patent risks, compliance with government regulations, dependence on key personnel and collaborative partners, competition, customer demand, management of growth, and the effectiveness of marketing by the Company. Reverse Stock Split On October 22, 2021, the Company effected a reverse stock split of the Company’s common stock on a 1-for-13.7 basis, or the Reverse Stock Split. In connection with the Reverse Stock Split, the conversion ratio for the Company’s convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. Accordingly, all common stock share and per share amounts, for all periods presented in these unaudited condensed consolidated financial statements, have been retroactively adjusted, to reflect this reverse stock split and adjustment of the convertible preferred stock conversion ratios. Initial Public Offering On November 2, 2021, the Company completed its initial public offering, or the IPO, in which it issued and sold 6,210,000 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares at a price to the public of $ 14.00 per share for aggregate gross proceeds of $ 86.9 million. The Company received approximately $ 78.3 million in net proceeds after deducting underwriting discounts, commissions and offering expenses. Liquidity Through September 30, 2022, the Company has funded its operations primarily with proceeds from the initial closings and additional closings of its convertible preferred stock financings, through its license agreements, and through its IPO. The Company has incurred recurring losses and negative operating cash flows from operations since its inception, including net losses of $ 42.2 million and $ 23.6 million for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, the Company had cash and cash equivalents and marketable securities of $ 111.5 million and an accumulated deficit of $ 194.3 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these unaudited condensed consolidated financial statements for the nine months ended September 30, 2022 , the Company expects that its cash and cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of these condensed consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. In management’s opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, and cash flows. The financial data and other information disclosed in these notes related to the three months and nine months ended September 30, 2022 and 2021 are also unaudited. The unaudited condensed results of operations are not necessarily indicative of the operating results that may occur for the full fiscal year ending December 31, 2022 . Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission, or the SEC. Management believes that the disclosures provided here are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K. Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2021, in the Company's Annual Report on Form 10-K filed with the SEC on March 23, 2022. There have been no changes to the Company's significant accounting policies except as noted below. Marketable Securities All marketable securities have original maturities greater than 90 days. The Company has classified its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value. Unrealized gains and losses are reported as the accumulated other comprehensive items in stockholders’ equity. Amortization and accretion of premiums and discounts are recorded in other income (expense) within the consolidated statements of operations and comprehensive loss. Realized gains or losses are included in interest income or interest expense, respectively. If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence such as industry, financial inputs, and capital markets data to evaluate the extent to which the decline is other than temporary and, if so, marks the investment to market on the Company’s condensed consolidated statement of operations and comprehensive loss. Recently Adopted Accounting Pronouncements The Company assessed the recent accounting pronouncements for the nine months ended September 30, 2022 and determined no pronouncements have material impact to the condensed consolidated financial statements. Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which was subsequently amended in November 2018 through ASU No. 2018-19, “Codification Improvements to Topic 326, Financial Instruments—Credit Losses.” ASU No. 2016-13 will require entities to estimate lifetime expected credit losses for trade and other receivables, net investments in leases, financing receivables, debt securities and other instruments, which will result in earlier recognition of credit losses. Further, the new credit loss model will affect how entities in all industries estimate their allowance for losses for receivables that are current with respect to their payment terms. ASU No. 2018-19 further clarifies that receivables arising from operating leases are not within the scope of Topic 326. Instead, impairment from receivables of operating leases should be accounted for in accordance with Topic 842, Leases. As per the latest ASU 2020-02, FASB deferred the timelines for certain small public and private entities, thus the new guidance will be adopted by the Company for the annual reporting period beginning January 1, 2023, including interim periods within that annual reporting period. The standard will apply as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The Company does not expect adoption of this new guidance to have a material impact on its results of operations, financial condition, and financial statement disclosures. |
Fair Value of Assets and Liabil
Fair Value of Assets and Liabilities | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Assets and Liabilities | 3. Fair Value of Assets and Liabilities The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2022 and December 31, 2021 (in thousands): Description September 30, Quoted prices markets Significant Significant Financial assets Cash equivalents: Money market funds $ 58,100 $ 58,100 $ — $ — Marketable securities: Commercial paper 27,880 — 27,880 — Corporate bonds 16,535 — 16,535 — U.S. Government agencies 5,994 — 5,994 — Total financial assets $ 108,509 $ 58,100 $ 50,409 $ — Description December 31, Quoted prices markets Significant Significant Financial assets Cash equivalents: Money market funds $ 24,063 $ 24,063 $ — $ — Total financial assets $ 24,063 $ 24,063 $ — $ — |
Property and Equipment, Net
Property and Equipment, Net | 9 Months Ended |
Sep. 30, 2022 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment, Net | 4. Property and Equipment, Net Property and equipment, net, consisted of the following (in thousands): September 30, December 31, Assets under construction $ 1,976 $ 2,365 IT equipment 103 85 Leasehold improvements — 13 Lab equipment 6,937 5,489 Office furniture — 63 $ 9,016 $ 8,015 Less—accumulated depreciation ( 3,541 ) ( 2,764 ) Property and equipment, net $ 5,475 $ 5,251 Depreciation expense was $ 0.3 million and $ 0.2 million for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was $ 0.9 million and $ 0.6 million for the nine months ended September 30, 2022 and 2021 , respectively. |
Prepaid Expenses and Other Curr
Prepaid Expenses and Other Current Assets | 9 Months Ended |
Sep. 30, 2022 | |
Prepaid Expense and Other Assets, Current [Abstract] | |
Prepaid Expenses and Other Current Assets | 5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): September 30, December 31, Prepaid insurance $ 417 $ 2,734 Prepaid research and development expenses 3,460 1,754 Prepaid license agreements 24 64 Other 306 66 Prepaid expenses and other current assets $ 4,207 $ 4,618 |
Marketable Securities
Marketable Securities | 9 Months Ended |
Sep. 30, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Marketable Securities | 6. Marketable Securities Marketable securities consist of the following (in thousands): September 30, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 27,880 $ — $ — $ 27,880 Corporate bonds 16,675 — ( 140 ) $ 16,535 U.S. Government agencies 6,001 — ( 7 ) $ 5,994 Total $ 50,556 $ — $ ( 147 ) $ 50,409 There were no impairments of the Company’s assets measured and carried at fair value dur ing the nine months ended September 30, 2022 . |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 9 Months Ended |
Sep. 30, 2022 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Other Current Liabilities | 7. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): September 30, December 31, Accrued research and development expenses $ 2,189 $ 1,686 Accrued compensation 2,648 2,147 Other 461 506 Accrued expenses and other current liabilities $ 5,298 $ 4,339 |
Equity
Equity | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Equity | 8. Equity The Company had 150,000,000 authorized shares of common stock, par value $ 0.00001 per share, of which 29,283,285 and 29,211,643 shares were issued and outstanding at September 30, 2022 and December 31, 2021, respectively. Upon closing of the IPO on November 2, 2021, all of the Company's outstanding shares of convertible preferred stock automatically converted into 22,550,561 shares of common stock. In addition, the Company authorized 10,000,000 shares of preferred stock, par value $ 0.00001 per share, all of which shares of preferred stock will be undesignated. |
Stock-Based Compensation
Stock-Based Compensation | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Stock-Based Compensation | 9. Stock-Based Compensation 2018 Stock Option and Incentive Plan On December 12, 2018, the Company adopted the Aura Biosciences, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan will expire in 2028. Under the 2018 Plan, Aura may grant incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and stock right. The Board of Directors (the "Board") has determined not to make any further awards under the 2018 Plan as of November 2, 2021. However, the 2018 Plan will continue to govern outstanding equity awards granted thereunder. 2021 Stock Option and Incentive Plan The 2021 Stock Option and Incentive Plan, or the 2021 Plan, was adopted by the Board on October 7, 2021, approved by the Company’s stockholders on October 22, 2021 and became effective on November 1, 2021. The 2021 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code and options that do not so qualify. The number of shares initially reserved for issuance under the 2021 Plan was 3,352,166 , which increased on January 1, 2022 and will continue to increase each January 1 thereafter, by 5 % of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s compensation committee. The maximum number of shares of common stock that may be issued in the form of incentive stock options shall not exceed the initial limit, cumulatively increased on January 1, 2022 and on each January 1 thereafter by the lesser of the annual increase for such year or 3,352,166 shares of common stock. On January 1, 2022, the shares reserved for issuance was increased to 4,812,748 shares. 2021 Employee Stock Purchase Plan The 2021 Employee Stock Purchase Plan, or the ESPP, was adopted by the Board on October 7, 2021, approved by the Company’s stockholders on October 22, 2021 and became effective on November 1, 2021. A total of 335,217 shares of common stock were initially reserved for issuance under this plan, which increased on January 1, 2022 and will continue to increase each January 1 thereafter through January 1, 2031, by the least of (i) 335,217 shares of common stock, (ii) 1 % of the outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the ESPP. On January 1, 2022, the shares reserved for issuance was increased to 627,333 shares. The purchase price of the shares under the ESPP are at 85 % of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the purchase date. As of September 30, 2022, 627,333 shares were available to be issued under the ESPP. The Company recognized $ 0.01 million share-based compensation expense related to the ESPP for the nine months ended September 30, 2022. Stock Options With the transfer of the available options from the 2018 Plan to the 2021 Plan, there were 3,435,004 options available for grant under the 2021 Plan at September 30, 2022. The Board is authorized to administer the 2021 Plan. In accordance with the provisions of the 2021 Plan, the Board determines the terms of Aura options and other awards issued pursuant thereto, including the following: ▪ which employees, directors and consultants shall be granted awards; ▪ the number of shares of common stock subject to options and other awards; ▪ the exercise price of each option, which generally shall not be less than fair market value of the common stock on the date of grant; ▪ the termination or cancellation provisions applicable to options; ▪ the terms and conditions of other awards, including conditions for repurchase, termination or cancellation, issue price and repurchase price; and ▪ all other terms and conditions upon which each award may be granted in accordance with the 2018 Plan. In addition, the Board may award restricted shares of common stock and restricted stock units to participants subject to such conditions and restrictions as it may determine. The Board or any committee to which the Board delegates authority may, with the consent of the affected plan participants, re-price or otherwise amend outstanding awards consistent with the terms of the 2021 Plan. The following table summarizes stock option activity under the 2018 Plan and 2021 Plan for the nine months ended September 30, 2022: Options Weighted- Weighted- Aggregate Intrinsic Outstanding at December 31, 2021 4,232,991 $ 7.43 8.66 $ 40,437 Granted 428,321 16.43 Exercised ( 71,642 ) 6.00 Cancelled/Forfeited ( 333,777 ) 11.36 Outstanding at September 30, 2022 4,255,893 $ 8.05 8.16 $ 42,994 Exercisable at September 30, 2022 1,603,397 $ 4.35 6.87 $ 22,071 The weighted-average grant date fair value of stock options granted during the nine months ended September 30, 2022 and 2021 was $ 11.09 and $ 3.97 per share, respectively. The fair value of options vested during the nine months ended September 30, 2022 and 2021 was $ 2.1 million and $ 1.0 million, respectively. The total intrinsic value of options exercised was $ 0.8 million and $ 0.01 million for the nine months ended September 30, 2022 and 2021, respectively. The Company has elected to use the Black-Scholes option pricing model to determine the fair value of options granted and generally recognizes the compensation cost of stock-based awards on a straight-line basis over the vesting period of the award. The determination of the fair value of stock-based payment awards utilizing the Black-Scholes option pricing model is affected by the estimated fair value of the Company’s common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate, and expected dividends. The fair value of the stock options issued for the nine months ended September 30, 2022 and 2021 was measured with the following weighted-average assumptions: Nine Months Ended Three Months Ended 2022 2021 Risk-free interest rate 2.73 % 1.06 % 3.08 % 1.00 % Expected term (years) 5.92 6.02 5.96 6.06 Expected volatility of the underlying stock 76.76 % 74.21 % 79.01 % 73.36 % Expected dividend rate — % — % — % — % Restricted Stock Units The Company has granted restricted stock units with service-based vesting conditions. Unvested shares of restricted common stock may not be sold or transferred by the holder. A summary of the restricted stock units activity during the nine months ended September 30, 2022 is as follows: Restricted Stock Units Weighted- Unvested at December 31, 2021 231,920 $ 14.00 Forfeited ( 26,192 ) 14.00 Unvested at September 30, 2022 205,728 $ 14.00 As a result of the 2021 Equity Incentive Plan, the Company granted restricted stock units which vest in increments of 25 % annually over a period of four years . No restricted stock units vested during the nine months ended September 30, 2022. Stock-based Compensation Expense The Company recorded stock-based compensation expense as follows (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Research and development $ 619 $ 157 $ 1,639 $ 263 General and administrative 1,093 $ 397 2,954 747 Total $ 1,712 $ 554 $ 4,593 $ 1,010 As of September 30, 2022 , there was $ 14.8 million of unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.69 years. As of September 30, 2022 , there was $ 2.2 million of unrecognized compensation expense related to restricted stock units, which is expected to be recognized over a weighted-average period of 3.08 years. |
Common Stock Warrants
Common Stock Warrants | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Common Stock Warrants | 10. Common Stock Warrants In February 2015 and May 2015, the Company issued warrants to purchase 1,650,098 and 887,536 shares of Series B convertible preferred stock, respectively, at an exercise price of $ 1.24235 per share (the "Series B Warrants"). Each Series B Warrant was immediately exercisable and expires ten years from the original date of issuance. Pursuant to FASB ASC Topic 480, Distinguishing Liabilities from Equity, the Series B Warrants were classified as a liability and were re-measured to fair value at each balance sheet date. A total of 173,827 of the Series B Warrants were outstanding and were converted into warrants to purchase 12,686 shares of common stock with an exercise price of $ 17.03 upon the completion of the IPO in November 2021. As a result, the 12,686 common stock warrants were converted into equity instruments and remain outstanding as of September 30, 2022. |
Compensation
Compensation | 9 Months Ended |
Sep. 30, 2022 | |
Retirement Benefits [Abstract] | |
Compensation | 11. Compensation In January 2012, the Company adopted the Aura Biosciences 401(k) Profit Sharing Plan and Trust (the “401(k) Plan”) for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. The Company makes matching contributions of 100 % of the first 6 % of employee contributions. The Company made matching contributions in the amount of $ 0.4 m illion and $ 0.2 million for the nine months ended September 30, 2022 and 2021 , respectively. |
Commitment and Contingencies
Commitment and Contingencies | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 12. Commitments and Contingencies Lease Commitments The Company has historically entered into lease arrangements for its facilities. The Company has one operating lease for its office and laboratory facility with required future minimum payments as of September 30, 2022 and one operating lease that was terminated in August 2022. For more information on these leases, please see sections below in this footnote. On March 31, 2021, the Company executed an amendment to the facility lease which included an extension of the expiration date of the original leased premises, the addition of 4,516 square feet of laboratory space with a commencement date of May 1, 2021 , and the addition of 1,000 square feet of laboratory space with a commencement date of June 15, 2021 . The lease term for the original and new spaces will expire on July 31, 2023 , with an option to renew for an additional 12 months . Upon the execution of the amendment, which was deemed to be a lease modification, the Company re-evaluated the assumptions made at the original lease commencement date. The Company determined the amendment consists of two separate contracts under ASC 842. One contract is related to the modification of term for the original space, and the other is related to a new right-of-use for the two additional spaces, which are to be accounted for as new leases. The Company remeasured the lease liability and corresponding right-of-use asset for the original space as of the effective date of the amendment to reflect the extended term and recorded in the second quarter of 2021 an additional right-of-use asset and lease liability upon lease commencement of each of the additional space. In August 2022, the Company entered into a termination agreement with the landlord to the end lease effective August 31, 2022, which resulted in the Company paying the landlord a termination expense of $ 0.3 million. The Company recognized a loss on the lease of $ 0.3 million which was recorded as a loss on disposal of assets on the condensed statements of operations and comprehensive loss and derecognized $ 0.6 million in lease liabilities and corresponding right-of-use asset on the condensed balance sheets. On May 16, 2022, the Company entered into an office and laboratory lease in Boston, MA with an initial 10 -year term and one renewal option to extend the lease for an additional seven years . The lease commenced on August 1, 2022 , and estimated payments due under the initial term total $ 35.2 million. The lease requires a letter of credit totaling $ 0.8 million which is classified as long-term restricted cash and deposits on the condensed consolidated balance sheet. The landlord will reimburse the Company up to $ 0.5 million for certain costs related to expansion of the laboratory space. As of September 30, 2022, the Company has incurred an immaterial amount of expenses related to the expansion. The Company also leases office and laboratory equipment for which the related expense is immaterial. The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s leases for the three and nine months ended September 30, 2022 and 2021 (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Lease Cost Amortization of finance right-of-use assets $ — $ — $ — $ 11 Operating lease costs 692 154 1,001 370 Variable lease costs 566 90 903 233 Short-term lease costs 2 — 6 — Total lease costs $ 1,260 $ 244 $ 1,910 $ 614 Cash paid for amounts included in the measurement of lease liability—finance leases $ — $ 15 Cash paid for amounts included in the measurement of lease liabilities—operating leases $ 922 $ 367 Weighted-average remaining lease term—finance leases (years) — — Weighted-average remaining lease term—operating leases (years) 9.84 1.83 Weighted-average discount rate—finance leases — 7.94 % Weighted-average discount rate—operating leases 10.71 % 3.51 % The following table reconciles the future minimum commitments to the Company’s operating lease liabilities at September 30, 2022 (in thousands): Operating lease payments as of 2022 $ 768 2023 3,112 2024 3,205 2025 3,301 2026 3,400 Thereafter 20,932 Total lease payments 34,718 Less: interest ( 13,647 ) Total operating lease liabilities at September 30, 2022 21,071 Less: current portion of lease liabilities 2,942 Lease liabilities, net of current portion $ 18,129 Laser Purchasing Commitment On April 5, 2019, the Company entered into a purchase agreement for equipment with future commitments payable in three installments of € 0.2 million each. The first two installments of € 0.2 million were paid by the Company in April 2019 and August 2019. Upon receipt of the laser systems, the Company will assess whether the laser systems have an alternative future use and, if so, will capitalize the lasers as a component of fixed assets. License Agreements The Company has entered into the following key agreements that relate to the core technology under development: LI-COR Exclusive License and Supply Agreement In January 2014, the Company entered into an Exclusive License and Supply Agreement, or the LI-COR Exclusive License agreement with LI-COR, Inc. (LI-COR) for the license of IRDye 700DC and related licensed patents for the treatment and diagnosis of ocular cancers in humans as amended in January 2016, July 2017, April 2018 and April 2019. The LI-COR Exclusive License Agreement required a one-time upfront license issue fee of $ 0.1 million and aggregate milestone payments of up to $ 0.2 million upon certain regulatory and development milestones. The Company is also required to pay LI-COR low-single digit royalties on net sales. The term of the LI-COR Exclusive Agreement expires on a country-by-country basis, until the longer of (i) ten years from the first commercial sale of a licensed product in such country and (ii) the last to expire valid claim in such country. The Company recognized no expenses related to this agreement and related amendments for the three and nine months ended September 30, 2022 and 2021, respectively. LI-COR Non-Exclusive License and Supply Agreement In December 2014, the Company entered into a Non-Exclusive License Agreement with LI-COR for the supply of IRDye 700DX to the Company for the treatment and diagnosis of non-ocular solid tumor cancers in humans. Under the 2014 Non-Exclusive, the Company paid a license issue fee of $ 0.03 million on the effective date. The Company must also pay LI-COR a non-refundable, non-creditable fee of $ 0.03 million per each licensed product upon pre-IND designation, as defined of such licensed product, aggregate milestone payments of up to $ 0.3 million upon certain regulatory and development milestones; and during the term, the Company must pay LI-COR a low-single digit percentage royalty on net sales. LI-COR receives 10% of all sublicensee income within 30 days of the Company’s receipt from the sublicensee. The 2014 Non-Exclusive Agreement also required the Company to make certain payments upon the achievement of specified development and commercial milestones of up to $ 0.4 million in aggregate. During the nine months ended September 30, 2022 and 2021, the Company recognized immaterial milestones related to this agreement. Life Technologies Corporation In December 2014, the Company entered into a non-exclusive, perpetual license agreement with Life Technologies Corporation, or the Life Technologies, which allows for five licensed products. Under this agreement the Company is required to pay an initial license fee of $ 0.1 million for each product. An annual development fee of $ 0.1 million is due within a year from payment of the initial license fee and due annually or earlier of (i) payment of a commercialization fee or (ii) all development work is terminated. The commercialization fee is a one-time, non-refundable, non-creditable fee of $ 0.3 million due upon receipt of approval of a licensed product. In the event of a change of control, there will be a change of control fee of $ 0.2 million. In January 2022, the Company entered into the First Amendment to the non-exclusive, perpetual license agreement with Life Technologies for use of the license in an additional indication. The cost of this amendment was a one-time fee of $ 0.05 million. During the nine months ended September 30, 2022 and 2021, the Company recognized $ 0.1 million and $ 0.03 million of expenses related to this agreement, respectively. Effective in September 2022, the Company entered into a new non-exclusive, perpetual license agreement with Life Technologies for licensed products. Under this agreement, the Company is required to pay an initial license fee of $ 0.4 million for the first licensed product and $ 0.5 million for each additional licensed product. In addition, the agreement allows the Company the right to sublicense which would lead to a $ 0.2 million payment for each sublicense per licensed product and a $ 0.03 million payment for use of the cell line document package. In the event of a change of control, there will be a change of control fee of $ 0.5 million. During the nine months ended September 30, 2022, the Company recognized $ 0.4 million of expenses related to this agreement. National Institute of Health (NIH)-Biologic Materials License Agreement In December 2010, the Company entered into a Biologic Materials License Agreement with NIH for a non-exclusive right to use materials described in Schiller et al., Virology 2004 Apr.10, 321(2):205-16. This agreement required a one-time non-refundable license issuance fee of $ 0.02 million. No future milestone payments or royalties are due under this agreement. National Institute of Health (NIH)-Collaboration Research and Development Agreement In July 2011, the Company entered into a Collaboration Research and Development Agreement (CRADA), with Dr. John Schiller at the NIH, for a period of two years with the rights to an exclusive license to all technology generated within the collaboration. Under this agreement, the Company is required to make annual payments of $ 0.03 million to fund the research activities, the first payment of which was paid within 30 days of the effective date. Subsequent payments are due within 30 days of the anniversary of the effective date. This agreement was first amended in 2012, 2013, 2014, 2015, 2016, 2018 and most recently in September of 2020. During the nine months ended September 30, 2022 and 2021 , the Company paid $ nil million and $ 0.03 million of research collaboration fees related to this agreement. A seventh amendment was made in October 2020, requiring payment of $ 0.04 million within 30 days of October 1, 2020, and another $ 0.03 million within 30 days of the 10th anniversary of the CRADA, which was paid in July 2021. This seventh amendment extended the term of the CRADA to September 30, 2022. The Company recognized no milestones related to this agreement and related amendments for the nine months ended September 30, 2022 and 2021. An eighth amendment was effective in September 2022, requiring payment of $ 0.04 million within 30 days of November 1, 2022, and payment of another $ 0.03 million within 30 days of the 12th anniversary of the CRADA, which will be in August 2023. This eighth amendment extended the term of the CRADA to September 30, 2024. During the nine months ended September 30, 2022, the Company recognized $ 0.04 million of expenses related to this agreement. National Institute of Health (NIH)-Exclusive Patent License Agreement In September 2013, the Company entered into an exclusive patent license agreement (the “NIH Exclusive License Agreement”) with the NIH, that required the Company to pay a license issue royalty of $ 0.1 million and reimburse the NIH for any patent expenses incurred. Under the agreement, the Company is required to make low single-digit percentage royalty payments based on specified levels of annual net sales of licensed products subject to certain specified reductions. The Company is required to make development and regulatory milestone payments of up to $ 0.7 million in aggregate and sales milestone payments up to $ 0.6 million in the aggregate. The Company is also required to pay NIH a mid-single to low teen-digit percentage of any sublicensing revenue the Company receives. Additionally, the Company’s payment obligations to the NIH are subject to an annual minimum royalty payment of low five figures. The Company recognized $ nil million and $ 0.03 million for patent licensing fees for the nine months ended September 30, 2022 and 2021, respectively. In 2015, 2018 and 2019, the Company amended its exclusive patent license to include updates on the status of the commercial development and update/expand the list of licensed patents and patent applications. Each of those amendments required a $ 0.03 million payment that the Company paid. Inserm-Transfert License Agreement In November 2009, the Company entered into an exclusive, royalty-bearing patent license agreement with Inserm-Transfert of France. The agreement expires on a country by country basis based on the last to expire any patent encompassed within the scope of the patent rights or 10 years from the date of the first commercial sales by the Company, whichever is later. The IND filing milestone of € 0.01 million was accrued in 2016 and paid in 2017 by the Company. The milestones for the successful Phase I, II and III clinical trials are based on receiving a final report and achieving the primary endpoints defined in that trial, and those milestones have not been achieved as of September 30, 2022 . Upon the sublicense by the Company of a product for which royalties are payable under the agreement, low- to mid-single-digit royalty payments would be due by the Company. The non-milestone payments in this agreement are subject to an anti-stacking clause. The Company did no t incur any expense in the nine months ended September 30, 2022 and 2021. Clearside In July 2019, the Company entered into an exclusive license agreement with Clearside Biomedical, Inc. (“Clearside”), for the license of Clearside’s Suprachoroidal Microneedle Technology for use in the treatment of indeterminate lesions and choroidal tumors. Upon execution of the License Agreement, the Company paid Clearside an upfront payment of $ 0.1 million which was expensed as incurred. Under the Clearside License Agreement, the Company is required to pay milestones up to $ 21.0 million in the aggregate upon the achievement of specified regulatory and development milestones, and upon the achievement of certain commercial sales milestones. The Company is also required to pay low to mid-single digit royalties on net sales. If the Company sublicenses a product for which royalties are payable, then the Company is required to pay the greater of 20 % received or low single digit royalties on net sales. The Clearside License agreement expires on a country-by-country basis upon the later of the last to expire patent or ten years from the date of the first commercial sale of a product. The Company recognized no expenses related to this agreement and related amendments for the nine months ended September 30, 2022 and 2021 . |
Net Loss Per Share
Net Loss Per Share | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | 13. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is the same as basic net loss per share for the periods presented since the effects of potentially dilutive securities are antidilutive given the net loss of the Company. The Company has calculated basic and diluted net loss per share for the three and nine months ended September 30, 2022 and 2021 as follows (in thousands, except share and per share data): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator: Net loss $ ( 15,901 ) $ ( 8,838 ) $ ( 42,204 ) $ ( 23,617 ) Less: Accruals of dividends of preferred stock — ( 3,668 ) — ( 9,627 ) Net loss attributable to common stockholders—basic and diluted $ ( 15,901 ) $ ( 12,506 ) $ ( 42,204 ) $ ( 33,244 ) Denominator: Weighted-average common stock outstanding 29,273,577 441,448 29,246,449 426,604 Net loss per share attributable to common stockholders—basic and diluted $ ( 0.54 ) $ ( 28.33 ) $ ( 1.44 ) $ ( 77.93 ) The following potentially dilutive securities were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been antidilutive: Nine Months Ended 2022 2021 Convertible preferred stock — 22,550,561 Stock options to purchase common stock 4,255,893 3,164,949 Restricted stock units that vest into common stock 205,728 — Warrants to purchase preferred stock — 12,686 Warrants to purchase common stock 12,686 — Total potential dilutive shares 4,474,307 25,728,196 |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 14. Income Taxes The Company estimates an annual effective tax rate of 0 % for the year ending December 31, 2022 as the Company incurred losses for the three and nine months ended September 30, 2022, and is forecasting additional losses through the remainder of fiscal year ending December 31, 2022, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2022. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method. Due to the Company’s history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company does not currently believe that realization of its deferred tax assets is more likely than not. As of September 30, 2022 , the Company had no unrecognized income tax benefits that would reduce the Company’s effective tax rate if recognized. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | 15. Subsequent Events Subsequent events have been evaluated through the date of filing of the unaudited condensed consolidated financial statements. The Company has identified the following subsequent events that require disclosure. Financing On November 1, 2022, the Company filed a shelf registration statement on Form S-3, or the 2022 Shelf, with the SEC in relation to the registration of up to an aggregate offering price of $ 250.0 million of common stock, preferred stock, debt securities, warrants and units or any combination thereof. The Company also simultaneously entered into an Open Market Sale Agreement SM , or the Sales Agreement, with Jefferies LLC., or the Sales Agent, to provide for the offering, issuance and sale by the Company of up to an aggregate of $ 75.0 million of its common stock from time to time in “at-the-market” offerings under the 2022 Shelf and subject to the limitations thereof. The Company will pay to the Sales Agent cash commissions of up to 3.0 percent of the gross proceeds of sales of common stock under the Sales Agreement. The Company has not issued any shares or received any proceeds from any offerings under the 2022 Shelf through November 10, 2022. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. In management’s opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company’s financial position, results of operations, and cash flows. The financial data and other information disclosed in these notes related to the three months and nine months ended September 30, 2022 and 2021 are also unaudited. The unaudited condensed results of operations are not necessarily indicative of the operating results that may occur for the full fiscal year ending December 31, 2022 . Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission, or the SEC. Management believes that the disclosures provided here are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K. |
Significant Accounting Policies | Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2021, in the Company's Annual Report on Form 10-K filed with the SEC on March 23, 2022. There have been no changes to the Company's significant accounting policies except as noted below. |
Marketable Securities | Marketable Securities All marketable securities have original maturities greater than 90 days. The Company has classified its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value. Unrealized gains and losses are reported as the accumulated other comprehensive items in stockholders’ equity. Amortization and accretion of premiums and discounts are recorded in other income (expense) within the consolidated statements of operations and comprehensive loss. Realized gains or losses are included in interest income or interest expense, respectively. If any adjustment to fair value reflects a decline in value of the investment, the Company considers all available evidence such as industry, financial inputs, and capital markets data to evaluate the extent to which the decline is other than temporary and, if so, marks the investment to market on the Company’s condensed consolidated statement of operations and comprehensive loss. |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements The Company assessed the recent accounting pronouncements for the nine months ended September 30, 2022 and determined no pronouncements have material impact to the condensed consolidated financial statements. |
Accounting Pronouncements Not Yet Adopted | Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which was subsequently amended in November 2018 through ASU No. 2018-19, “Codification Improvements to Topic 326, Financial Instruments—Credit Losses.” ASU No. 2016-13 will require entities to estimate lifetime expected credit losses for trade and other receivables, net investments in leases, financing receivables, debt securities and other instruments, which will result in earlier recognition of credit losses. Further, the new credit loss model will affect how entities in all industries estimate their allowance for losses for receivables that are current with respect to their payment terms. ASU No. 2018-19 further clarifies that receivables arising from operating leases are not within the scope of Topic 326. Instead, impairment from receivables of operating leases should be accounted for in accordance with Topic 842, Leases. As per the latest ASU 2020-02, FASB deferred the timelines for certain small public and private entities, thus the new guidance will be adopted by the Company for the annual reporting period beginning January 1, 2023, including interim periods within that annual reporting period. The standard will apply as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The Company does not expect adoption of this new guidance to have a material impact on its results of operations, financial condition, and financial statement disclosures. |
Fair Value of Assets and Liab_2
Fair Value of Assets and Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis | The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2022 and December 31, 2021 (in thousands): Description September 30, Quoted prices markets Significant Significant Financial assets Cash equivalents: Money market funds $ 58,100 $ 58,100 $ — $ — Marketable securities: Commercial paper 27,880 — 27,880 — Corporate bonds 16,535 — 16,535 — U.S. Government agencies 5,994 — 5,994 — Total financial assets $ 108,509 $ 58,100 $ 50,409 $ — Description December 31, Quoted prices markets Significant Significant Financial assets Cash equivalents: Money market funds $ 24,063 $ 24,063 $ — $ — Total financial assets $ 24,063 $ 24,063 $ — $ — |
Property and Equipment, Net (Ta
Property and Equipment, Net (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment, Net | Property and equipment, net, consisted of the following (in thousands): September 30, December 31, Assets under construction $ 1,976 $ 2,365 IT equipment 103 85 Leasehold improvements — 13 Lab equipment 6,937 5,489 Office furniture — 63 $ 9,016 $ 8,015 Less—accumulated depreciation ( 3,541 ) ( 2,764 ) Property and equipment, net $ 5,475 $ 5,251 |
Prepaid Expenses and Other Cu_2
Prepaid Expenses and Other Current Assets (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Prepaid Expense and Other Assets, Current [Abstract] | |
Schedule of Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets consisted of the following (in thousands): September 30, December 31, Prepaid insurance $ 417 $ 2,734 Prepaid research and development expenses 3,460 1,754 Prepaid license agreements 24 64 Other 306 66 Prepaid expenses and other current assets $ 4,207 $ 4,618 |
Marketable Securities (Tables)
Marketable Securities (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Summary of Marketable Securities | Marketable securities consist of the following (in thousands): September 30, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 27,880 $ — $ — $ 27,880 Corporate bonds 16,675 — ( 140 ) $ 16,535 U.S. Government agencies 6,001 — ( 7 ) $ 5,994 Total $ 50,556 $ — $ ( 147 ) $ 50,409 |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Payables and Accruals [Abstract] | |
Summary of Accrued Expenses and Other Current Liabilities | Accrued expenses and other current liabilities consisted of the following (in thousands): September 30, December 31, Accrued research and development expenses $ 2,189 $ 1,686 Accrued compensation 2,648 2,147 Other 461 506 Accrued expenses and other current liabilities $ 5,298 $ 4,339 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Summary of Combined Stock Option Activity under 2021 Plan | The following table summarizes stock option activity under the 2018 Plan and 2021 Plan for the nine months ended September 30, 2022: Options Weighted- Weighted- Aggregate Intrinsic Outstanding at December 31, 2021 4,232,991 $ 7.43 8.66 $ 40,437 Granted 428,321 16.43 Exercised ( 71,642 ) 6.00 Cancelled/Forfeited ( 333,777 ) 11.36 Outstanding at September 30, 2022 4,255,893 $ 8.05 8.16 $ 42,994 Exercisable at September 30, 2022 1,603,397 $ 4.35 6.87 $ 22,071 |
Schedule of Fair Value of Stock Options, Valuation Assumptions | The fair value of the stock options issued for the nine months ended September 30, 2022 and 2021 was measured with the following weighted-average assumptions: Nine Months Ended Three Months Ended 2022 2021 Risk-free interest rate 2.73 % 1.06 % 3.08 % 1.00 % Expected term (years) 5.92 6.02 5.96 6.06 Expected volatility of the underlying stock 76.76 % 74.21 % 79.01 % 73.36 % Expected dividend rate — % — % — % — % |
Schedule of Nonvested Restricted Stock Units Activity | A summary of the restricted stock units activity during the nine months ended September 30, 2022 is as follows: Restricted Stock Units Weighted- Unvested at December 31, 2021 231,920 $ 14.00 Forfeited ( 26,192 ) 14.00 Unvested at September 30, 2022 205,728 $ 14.00 |
Summary of Stock-Based Compensation Expense | The Company recorded stock-based compensation expense as follows (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Research and development $ 619 $ 157 $ 1,639 $ 263 General and administrative 1,093 $ 397 2,954 747 Total $ 1,712 $ 554 $ 4,593 $ 1,010 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Summary of Lease Costs | The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s leases for the three and nine months ended September 30, 2022 and 2021 (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Lease Cost Amortization of finance right-of-use assets $ — $ — $ — $ 11 Operating lease costs 692 154 1,001 370 Variable lease costs 566 90 903 233 Short-term lease costs 2 — 6 — Total lease costs $ 1,260 $ 244 $ 1,910 $ 614 Cash paid for amounts included in the measurement of lease liability—finance leases $ — $ 15 Cash paid for amounts included in the measurement of lease liabilities—operating leases $ 922 $ 367 Weighted-average remaining lease term—finance leases (years) — — Weighted-average remaining lease term—operating leases (years) 9.84 1.83 Weighted-average discount rate—finance leases — 7.94 % Weighted-average discount rate—operating leases 10.71 % 3.51 % |
Summary of Future Minimum Commitments of Operating Lease Liabilities | The following table reconciles the future minimum commitments to the Company’s operating lease liabilities at September 30, 2022 (in thousands): Operating lease payments as of 2022 $ 768 2023 3,112 2024 3,205 2025 3,301 2026 3,400 Thereafter 20,932 Total lease payments 34,718 Less: interest ( 13,647 ) Total operating lease liabilities at September 30, 2022 21,071 Less: current portion of lease liabilities 2,942 Lease liabilities, net of current portion $ 18,129 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Summary of Basic and Diluted Net Loss Per Share | The Company has calculated basic and diluted net loss per share for the three and nine months ended September 30, 2022 and 2021 as follows (in thousands, except share and per share data): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator: Net loss $ ( 15,901 ) $ ( 8,838 ) $ ( 42,204 ) $ ( 23,617 ) Less: Accruals of dividends of preferred stock — ( 3,668 ) — ( 9,627 ) Net loss attributable to common stockholders—basic and diluted $ ( 15,901 ) $ ( 12,506 ) $ ( 42,204 ) $ ( 33,244 ) Denominator: Weighted-average common stock outstanding 29,273,577 441,448 29,246,449 426,604 Net loss per share attributable to common stockholders—basic and diluted $ ( 0.54 ) $ ( 28.33 ) $ ( 1.44 ) $ ( 77.93 ) |
Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share | The following potentially dilutive securities were excluded from the computation of the diluted net loss per share for the periods presented because their effect would have been antidilutive: Nine Months Ended 2022 2021 Convertible preferred stock — 22,550,561 Stock options to purchase common stock 4,255,893 3,164,949 Restricted stock units that vest into common stock 205,728 — Warrants to purchase preferred stock — 12,686 Warrants to purchase common stock 12,686 — Total potential dilutive shares 4,474,307 25,728,196 |
Description of Business - Addit
Description of Business - Additional Information (Details) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | |||||||||
Nov. 02, 2021 USD ($) $ / shares shares | Oct. 22, 2021 | Sep. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Sep. 30, 2021 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Description Of Business [Line Items] | |||||||||||
Reverse stock split description | On October 22, 2021, the Company effected a reverse stock split of the Company’s common stock on a 1-for-13.7 basis, or the Reverse Stock Split. | ||||||||||
Reverse stock split, conversion ratio | 0.072993 | ||||||||||
Net losses | $ 15,901 | $ 13,468 | $ 12,835 | $ 8,838 | $ 8,852 | $ 5,927 | $ 42,204 | $ 23,617 | |||
Cash and cash equivalents and marketable securities | 111,500 | 111,500 | |||||||||
Accumulated deficit | $ 194,341 | $ 194,341 | $ 152,137 | ||||||||
Initial Public Offering | |||||||||||
Description Of Business [Line Items] | |||||||||||
Share price | $ / shares | $ 14 | ||||||||||
Aggregate gross proceeds from IPO | $ 86,900 | ||||||||||
Net proceeds from the IPO | $ 78,300 | ||||||||||
Common Stock | Initial Public Offering | |||||||||||
Description Of Business [Line Items] | |||||||||||
Shares issued and sold | shares | 6,210,000 |
Fair Value of Assets and Liab_3
Fair Value of Assets and Liabilities - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Assets | ||
Financial assets | $ 108,509 | $ 24,063 |
Money Market Funds | ||
Assets | ||
Financial assets | 58,100 | 24,063 |
Commercial Paper | ||
Assets | ||
Financial assets | 27,880 | |
Corporate Bonds | ||
Assets | ||
Financial assets | 16,535 | |
U.S. Government Agencies | ||
Assets | ||
Financial assets | 5,994 | |
Level 1 | ||
Assets | ||
Financial assets | 58,100 | 24,063 |
Level 1 | Money Market Funds | ||
Assets | ||
Financial assets | 58,100 | $ 24,063 |
Level 2 | ||
Assets | ||
Financial assets | 50,409 | |
Level 2 | Commercial Paper | ||
Assets | ||
Financial assets | 27,880 | |
Level 2 | Corporate Bonds | ||
Assets | ||
Financial assets | 16,535 | |
Level 2 | U.S. Government Agencies | ||
Assets | ||
Financial assets | $ 5,994 |
Property and Equipment, Net - S
Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | $ 9,016 | $ 8,015 |
Less—accumulated depreciation | (3,541) | (2,764) |
Property and equipment, net | 5,475 | 5,251 |
Assets Under Construction | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 1,976 | 2,365 |
IT Equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 103 | 85 |
Leasehold Improvements | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 13 | |
Lab Equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | $ 6,937 | 5,489 |
Office Furniture | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | $ 63 |
Property and Equipment, Net - A
Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Property, Plant and Equipment [Abstract] | ||||
Depreciation expense | $ 300 | $ 200 | $ 854 | $ 601 |
Prepaid Expenses and Other Cu_3
Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Prepaid Expense and Other Assets, Current [Abstract] | ||
Prepaid insurance | $ 417 | $ 2,734 |
Prepaid research and development expenses | 3,460 | 1,754 |
Prepaid license agreements | 24 | 64 |
Other | 306 | 66 |
Prepaid expenses and other current assets | $ 4,207 | $ 4,618 |
Marketable Securities - Summary
Marketable Securities - Summary of Marketable Securities (Details) $ in Thousands | Sep. 30, 2022 USD ($) |
Marketable securities [Line items] | |
Amortized Cost | $ 50,556 |
Unrealized Losses | (147) |
Fair Value | 50,409 |
Commercial Paper | |
Marketable securities [Line items] | |
Amortized Cost | 27,880 |
Fair Value | 27,880 |
Corporate Bonds | |
Marketable securities [Line items] | |
Amortized Cost | 16,675 |
Unrealized Losses | (140) |
Fair Value | 16,535 |
U.S. Government Agencies | |
Marketable securities [Line items] | |
Amortized Cost | 6,001 |
Unrealized Losses | (7) |
Fair Value | $ 5,994 |
Marketable Securities - Additio
Marketable Securities - Additional Information (Details) | 9 Months Ended |
Sep. 30, 2022 USD ($) | |
Investments, Debt and Equity Securities [Abstract] | |
Impairments of asset | $ 0 |
Accrued Expenses and Other Cu_3
Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Payables and Accruals [Abstract] | ||
Accrued research and development expenses | $ 2,189 | $ 1,686 |
Accrued compensation | 2,648 | 2,147 |
Other | 461 | 506 |
Accrued expenses and other current liabilities | $ 5,298 | $ 4,339 |
Convertible Preferred Stock - A
Convertible Preferred Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2021 | Sep. 30, 2021 | Nov. 02, 2021 | Jun. 30, 2021 | Dec. 31, 2020 | |
Temporary Equity [Line Items] | |||||
Convertible preferred stock, shares authorized | 10,000,000 | ||||
Convertible preferred stock, par value | $ 0.00001 | ||||
Series A Convertible Preferred Stock | |||||
Temporary Equity [Line Items] | |||||
Convertible preferred stock, shares outstanding | 1,701,141 | 1,701,141 | 1,701,141 | 1,701,141 | |
Series A-1 Convertible Preferred Stock | |||||
Temporary Equity [Line Items] | |||||
Convertible preferred stock, shares outstanding | 3,298,732 | 3,298,732 | 3,298,732 | 3,298,732 | |
Series A-2 Convertible Preferred Stock | |||||
Temporary Equity [Line Items] | |||||
Convertible preferred stock, shares outstanding | 4,324,998 | 4,324,998 | 4,324,998 | 4,324,998 | |
Series B Convertible Preferred Stock | |||||
Temporary Equity [Line Items] | |||||
Convertible preferred stock, shares outstanding | 22,531,819 | 22,531,819 | 22,531,819 | 22,531,819 | |
Series E Convertible Preferred Stock | |||||
Temporary Equity [Line Items] | |||||
Convertible preferred stock, shares outstanding | 102,671,041 | 102,671,041 | 102,671,041 | ||
Issuance of convertible preferred stock, Shares | 102,671,041 | ||||
Proceeds from issuance of convertible preferred stock | $ 80,246 | ||||
Offering costs | $ 232 |
Equity - Additional Information
Equity - Additional Information (Details) - $ / shares | Nov. 02, 2021 | Sep. 30, 2022 | Dec. 31, 2021 |
Class of Stock [Line Items] | |||
Common stock, shares authorized | 150,000,000 | 150,000,000 | |
Common stock, par value | $ 0.00001 | $ 0.00001 | |
Common stock, shares issued | 29,283,285 | 29,211,643 | |
Common stock, shares outstanding | 29,283,285 | 29,211,643 | |
Convertible preferred stock, shares authorized | 10,000,000 | ||
Convertible preferred stock, par value | $ 0.00001 | ||
Common Stock | Initial Public Offering | |||
Class of Stock [Line Items] | |||
Number of common stock upon conversion of convertible preferred stock | 22,550,561 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | |||||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Jan. 01, 2022 | Nov. 01, 2021 | Jan. 01, 2021 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Weighted-average grant date fair value of stock options granted | $ 11.09 | $ 3.97 | |||||
Fair value of options vested | $ 2,100 | $ 1,000 | |||||
Total intrinsic value of options exercised | 800 | 10 | |||||
Unrecognized compensation expense related to stock options | $ 14,800 | $ 14,800 | |||||
Unrecognized compensation expense weighted average period | 2 years 8 months 8 days | ||||||
Share-based compensation expense | 1,712 | $ 554 | $ 4,593 | $ 1,010 | |||
Restricted Stock Units | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Unrecognized compensation expense related to stock options | $ 2,200 | $ 2,200 | |||||
Unrecognized compensation expense weighted average period | 3 years 29 days | ||||||
Restricted stock units vesting increments | 25% | ||||||
Restricted stock units vesting duration | 4 years | ||||||
Number of awards vested | 0 | ||||||
2021 Stock Option and Incentive Plan | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Number of shares reserved for issuance | 4,812,748 | 3,352,166 | |||||
Common stock outstanding percentage | 5% | 5% | |||||
Cumulative Increase In Shares Of Common Stock | 3,352,166 | 3,352,166 | |||||
2021 Employee Stock Purchase Plan | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Number of shares available for future issuance | 3,435,004 | 3,435,004 | |||||
Number of shares reserved for issuance | 627,333 | 627,333 | 335,217 | ||||
Share-based compensation expense | $ 10 | ||||||
Percentage of the lower of the fair market value of common stock | 85% | 85% | |||||
Common stock outstanding percentage | 1% | 1% |
Stock-Based Compensation - Summ
Stock-Based Compensation - Summary of stock option activity under the 2018 Plan to 2021 Plan (Details) - 2018 Plan and 2021 Plan Stock Option Activity plan $ / shares in Units, $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) $ / shares shares | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Options Outstanding, Beginning balance | shares | 4,232,991 | |
Options, Granted | shares | 428,321 | |
Options, Exercised | shares | (71,642) | |
Options, Cancelled or forfeited | shares | (333,777) | |
Options Outstanding, Ending balance | shares | 4,255,893 | 4,232,991 |
Options, Exercisable at September 30, 2022 | shares | 1,603,397 | |
Weighted Average Exercise Price, Beginning balance | $ / shares | $ 7.43 | |
Weighted Average Exercise Price, Granted | $ / shares | 16.43 | |
Weighted Average Exercise Price, Exercised | $ / shares | 6 | |
Weighted Average Exercise Price, Cancelled or forfeited | $ / shares | 11.36 | |
Weighted Average Exercise Price, Ending balance | $ / shares | 8.05 | $ 7.43 |
Weighted Average Exercise Price, Exercisable at September 30, 2022 | $ / shares | $ 4.35 | |
Weighted Average Remaining Contractual Term (years) | 8 years 1 month 28 days | 8 years 7 months 28 days |
Weighted Average Remaining Contractual Term (years), Exercisable at September 30, 2022 | 6 years 10 months 13 days | |
Aggregate Intrinsic Value, Outstanding | $ | $ 42,994 | $ 40,437 |
Aggregate Intrinsic Value, Exercisable September 30, 2022 | $ | $ 22,071 |
Stock-Based Compensation - Sche
Stock-Based Compensation - Schedule of Fair Value of Stock Options, Valuation Assumptions (Details) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Share-Based Payment Arrangement [Abstract] | ||||
Risk-free interest rate | 3.08% | 1% | 2.73% | 1.06% |
Expected term (years) | 5 years 11 months 15 days | 6 years 21 days | 5 years 11 months 1 day | 6 years 7 days |
Expected volatility | 79.01% | 73.36% | 76.76% | 74.21% |
Stock-Based Compensation - Su_2
Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units | 9 Months Ended |
Sep. 30, 2022 $ / shares shares | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Beginning Balance | shares | 231,920 |
Forfeited | shares | (26,192) |
Ending Balance | shares | 205,728 |
Unvested, Weighted -Average Grant Date Fair Value | $ / shares | $ 14 |
Forfeited, Weighted -Average Grant Date Fair Value | $ / shares | 14 |
Unvested, Weighted -Average Grant Date Fair Value | $ / shares | $ 14 |
Stock-Based Compensation - Su_3
Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Stock-based compensation expense | $ 1,712 | $ 554 | $ 4,593 | $ 1,010 |
Research and Development | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Stock-based compensation expense | 619 | 157 | 1,639 | 263 |
General and Administrative | ||||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||||
Stock-based compensation expense | $ 1,093 | $ 397 | $ 2,954 | $ 747 |
Common Stock Warrants - Additio
Common Stock Warrants - Additional Information (Details) - Series B Warrants - Common Stock Warrants - $ / shares | 1 Months Ended | ||||
May 31, 2015 | Feb. 28, 2015 | Sep. 30, 2022 | Nov. 02, 2021 | Jun. 30, 2021 | |
Class Of Warrant Or Right [Line Items] | |||||
Number of Warrants converted | 12,686 | ||||
Exercise price of warrants | $ 17.03 | ||||
Warrants outstanding | 12,686 | 173,827 | |||
Series B Convertible Preferred Stock | |||||
Class Of Warrant Or Right [Line Items] | |||||
Number of warrants issued | 887,536 | 1,650,098 | |||
Exercise price of warrants | $ 1.24235 | $ 1.24235 | |||
Warrants expiration period | 10 years | 10 years |
Compensation - Additional Infor
Compensation - Additional Information (Details) - 401(k) Plan - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Defined Contribution Plan Disclosure [Line Items] | ||
Matching contribution by employer, percentage | 100% | |
Employer matching contribution, percent of employees contribution | 6% | |
Matching contributions from employer | $ 0.4 | $ 0.2 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Details) € in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||||
Aug. 01, 2022 | May 16, 2022 USD ($) | Mar. 31, 2021 ft² | Apr. 05, 2019 EUR (€) Installment | Sep. 30, 2022 USD ($) OperatingLease | Aug. 31, 2022 USD ($) OperatingLease | Jan. 31, 2022 USD ($) | Oct. 31, 2020 USD ($) | Aug. 31, 2019 EUR (€) | Jul. 31, 2019 USD ($) | Apr. 30, 2019 EUR (€) | Dec. 31, 2014 USD ($) LicensedProduct | Jan. 31, 2014 USD ($) | Sep. 30, 2013 USD ($) | Jul. 31, 2011 USD ($) | Dec. 31, 2010 USD ($) | Nov. 30, 2009 | Sep. 30, 2022 USD ($) OperatingLease | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) OperatingLease | Sep. 30, 2021 USD ($) | Dec. 31, 2017 EUR (€) | |
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Estimated payments due | $ 34,718,000 | $ 34,718,000 | $ 34,718,000 | |||||||||||||||||||
Area of space leased | ft² | 4,516 | |||||||||||||||||||||
Lease commencement date | May 01, 2021 | |||||||||||||||||||||
Additional square feet of laboratory space | ft² | 1,000 | |||||||||||||||||||||
Additional leased space commencement date | Jun. 15, 2021 | |||||||||||||||||||||
Operating lease termination date | Jul. 31, 2023 | |||||||||||||||||||||
Lease existence of option to extend | true | |||||||||||||||||||||
Operating lease, option to extend term | 12 months | |||||||||||||||||||||
Operating lease liabilities | 21,071,000 | 21,071,000 | 21,071,000 | |||||||||||||||||||
Research and development expenses | 11,293,000 | $ 6,365,000 | 29,079,000 | $ 17,182,000 | ||||||||||||||||||
Biologic Materials License Agreement | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
One time non refundable license issuance fee | $ 20,000 | |||||||||||||||||||||
Milestone payments or royalties | $ 0 | |||||||||||||||||||||
National Institute of Health | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
License issue royalty fee | $ 100,000 | |||||||||||||||||||||
Sales milestone payments | 600,000 | |||||||||||||||||||||
Development and regulatory milestone payments | $ 700,000 | |||||||||||||||||||||
Patent licensing reimbursement fees | 30,000 | |||||||||||||||||||||
Expenses for patent licensing fees | 0 | 30,000 | ||||||||||||||||||||
Royalty Bearing Patent License Agreement | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Expenses | 0 | 0 | ||||||||||||||||||||
License agreement term | 10 years | |||||||||||||||||||||
Royalty Bearing Patent License Agreement | IND Filings | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Potential milestone payments | € | € 10 | |||||||||||||||||||||
Clearside | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Expenses | 0 | 0 | ||||||||||||||||||||
Upfront payment | $ 100,000 | |||||||||||||||||||||
Royalties on net sales | 20% | |||||||||||||||||||||
License agreement expiration period | 10 years | |||||||||||||||||||||
Clearside | Maximum | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Aggregate milestones payment | $ 21,000,000 | |||||||||||||||||||||
Termination Agreement | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Landlord termination expense | $ 300,000 | |||||||||||||||||||||
Recognized loss on lease | (300,000) | |||||||||||||||||||||
Operating lease liabilities | 600,000 | 600,000 | 600,000 | |||||||||||||||||||
LI-COR, Inc. | Exclusive License And Supply Agreement | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
One-time upfront license issuance fee | $ 100,000 | |||||||||||||||||||||
Research and development expenses | 0 | $ 0 | 0 | 0 | ||||||||||||||||||
License agreement term | 10 years | |||||||||||||||||||||
LI-COR, Inc. | Exclusive License And Supply Agreement | Maximum | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Aggregate milestone payments | $ 200,000 | |||||||||||||||||||||
LI-COR, Inc. | 2014 Non- Exclusive Agreement | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Research and development expenses | 40,000 | |||||||||||||||||||||
License issue fee | $ 30,000 | |||||||||||||||||||||
Milestone payments | 0 | 0 | ||||||||||||||||||||
Non-refundable, Non- creditable fee | 30,000 | |||||||||||||||||||||
LI-COR, Inc. | 2014 Non- Exclusive Agreement | Maximum | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Aggregate milestone payments | 300,000 | |||||||||||||||||||||
Payments for development and commercial milestones | $ 400,000 | |||||||||||||||||||||
Life Technologies | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Number of licensed products | LicensedProduct | 5 | |||||||||||||||||||||
Initial license fee | $ 100,000 | |||||||||||||||||||||
Initial license fee for first licensed product | 400,000 | |||||||||||||||||||||
Initial license fee for additional licensed product | 500,000 | |||||||||||||||||||||
Payment for sublicense | 200,000 | |||||||||||||||||||||
Payment for use of cell line document package | 30,000 | |||||||||||||||||||||
Annual development fee | 100,000 | |||||||||||||||||||||
Non-refundable, Non- creditable fee | 300,000 | |||||||||||||||||||||
Change of control fees | 500,000 | $ 200,000 | ||||||||||||||||||||
One time perpetual license agreement fee | $ 50,000 | |||||||||||||||||||||
Expenses | 100,000 | 30,000 | ||||||||||||||||||||
Expense related to agreement including sublicense | 400,000 | |||||||||||||||||||||
Dr. John Schiller | 2014 Non- Exclusive Agreement | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Required amendment payment | $ 40,000 | 40,000 | 40,000 | |||||||||||||||||||
Dr. John Schiller | Collaboration Research and Development Agreement | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Annual development fee | $ 30,000 | |||||||||||||||||||||
Agreement term | 2 years | |||||||||||||||||||||
First payment due | 30 days | |||||||||||||||||||||
Subsequent payments due | 30 days | |||||||||||||||||||||
Research collaboration fees | 0 | $ 30,000 | ||||||||||||||||||||
Required amendment payment | $ 40,000 | |||||||||||||||||||||
Required amendment payment due period | 30 days | 30 days | ||||||||||||||||||||
Dr. John Schiller | Collaboration Research and Development Agreement | 10th Anniversary | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Required amendment payment | $ 30,000 | $ 30,000 | $ 30,000 | $ 30,000 | ||||||||||||||||||
Required amendment payment due period | 30 days | 30 days | ||||||||||||||||||||
Office and Laboratory Facility | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Number of operating lease | OperatingLease | 1 | 1 | 1 | |||||||||||||||||||
Number of operating lease terminated | OperatingLease | 1 | |||||||||||||||||||||
Estimated payments due | $ 35,200,000 | |||||||||||||||||||||
Lease term | 10 years | |||||||||||||||||||||
Lease commencement date | Aug. 01, 2022 | |||||||||||||||||||||
Lease existence of option to extend | true | |||||||||||||||||||||
Operating lease, option to extend term | 7 years | |||||||||||||||||||||
Letters of credit | $ 800,000 | |||||||||||||||||||||
Maximum reimbursement cost | $ 500,000 | |||||||||||||||||||||
Laser System | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Purchase agreement, commitments payable in each installment | € | € 200 | |||||||||||||||||||||
Purchase agreement, number of payment installments | Installment | 3 | |||||||||||||||||||||
Laser System | Installment One | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Purchase agreement, installment amount paid | € | € 200 | |||||||||||||||||||||
Laser System | Installment Two | ||||||||||||||||||||||
Lessee, Lease, Description [Line Items] | ||||||||||||||||||||||
Purchase agreement, installment amount paid | € | € 200 |
Commitments and Contingencies_2
Commitments and Contingencies - Summary of Lease Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Leases [Abstract] | ||||
Amortization of finance right-of-use assets | $ 11 | |||
Operating lease costs | $ 692 | $ 154 | $ 1,001 | 370 |
Variable lease costs | 566 | 90 | 903 | 233 |
Short-term lease costs | 2 | 6 | ||
Total lease costs | $ 1,260 | $ 244 | 1,910 | 614 |
Cash paid for amounts included in the measurement of lease liability—finance leases | 15 | |||
Cash paid for amounts included in the measurement of lease liabilities--operating leases | $ 922 | $ 367 | ||
Weighted-average remaining lease term—operating leases (years) | 9 years 10 months 2 days | 1 year 9 months 29 days | 9 years 10 months 2 days | 1 year 9 months 29 days |
Weighted-average discount rate—finance leases | 7.94% | 7.94% | ||
Weighted-average discount rate—operating leases | 10.71% | 3.51% | 10.71% | 3.51% |
Commitments and Contingencies-
Commitments and Contingencies- Schedule of Fair Value of Financial Assets and Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
2022 | $ 768 | |
2023 | 3,112 | |
2024 | 3,205 | |
2025 | 3,301 | |
2026 | 3,400 | |
Thereafter | 20,932 | |
Total lease payments | 34,718 | |
Less: interest | (13,647) | |
Total operating lease liabilities at September 30, 2022 | 21,071 | |
Current portion of operating lease liabilities | 2,942 | $ 615 |
Lease liabilities, net of current portion | $ 18,129 | $ 360 |
Net Loss Per Share - Summary of
Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Numerator: | ||||||||
Net loss | $ (15,901) | $ (13,468) | $ (12,835) | $ (8,838) | $ (8,852) | $ (5,927) | $ (42,204) | $ (23,617) |
Less: Accruals of dividends of preferred stock | (3,668) | (9,627) | ||||||
Net loss attributable to common stockholders - basic and diluted | $ (15,901) | $ (12,506) | $ (42,204) | $ (33,244) | ||||
Denominator: | ||||||||
Weighted average common stock outstanding - basic | 29,273,577 | 441,448 | 29,246,449 | 426,604 | ||||
Weighted average common stock outstanding - diluted | 29,273,577 | 441,448 | 29,246,449 | 426,604 | ||||
Net loss per share attributable to common stockholders - basic | $ (0.54) | $ (28.33) | $ (1.44) | $ (77.93) | ||||
Net loss per share attributable to common stockholders - diluted | $ (0.54) | $ (28.33) | $ (1.44) | $ (77.93) |
Net Loss Per Share - Summary _2
Net Loss Per Share - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Total potential dilutive shares | 4,474,307 | 25,728,196 |
Convertible Preferred Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Total potential dilutive shares | 22,550,561 | |
Stock Options to Purchase Common Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Total potential dilutive shares | 4,255,893 | 3,164,949 |
Restricted Stock Units that Vest into Common Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Total potential dilutive shares | 205,728 | |
Warrants to Purchase Preferred Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Total potential dilutive shares | 12,686 | |
Warrants to Purchase Common Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Total potential dilutive shares | 12,686 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) | 3 Months Ended | 9 Months Ended |
Sep. 30, 2022 USD ($) | Sep. 30, 2022 USD ($) | |
Income Tax Disclosure [Abstract] | ||
Effective tax rate | 0% | 0% |
Unrecognized income tax benefits that would reduce effective tax rate if recognized | $ 0 | $ 0 |
Subsequent Events - (Additional
Subsequent Events - (Additional Information) (Details) - Subsequent Event [Member] $ in Millions | Nov. 01, 2022 USD ($) |
Subsequent Event [Line Items] | |
Aggregate offering price | $ 250 |
At-the-Market Offering [Member] | |
Subsequent Event [Line Items] | |
Sale of common stock through agreement | $ 75 |
Percentage of sales commission | 3% |